RU2011137516A - SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOGEPT [c] CHROMEN-3-ILSULFAMATE AND ITS POLYFORM - Google Patents
SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOGEPT [c] CHROMEN-3-ILSULFAMATE AND ITS POLYFORM Download PDFInfo
- Publication number
- RU2011137516A RU2011137516A RU2011137516/04A RU2011137516A RU2011137516A RU 2011137516 A RU2011137516 A RU 2011137516A RU 2011137516/04 A RU2011137516/04 A RU 2011137516/04A RU 2011137516 A RU2011137516 A RU 2011137516A RU 2011137516 A RU2011137516 A RU 2011137516A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- compound according
- theta
- chromen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Abstract
1. Твердая фармацевтическая композиция, содержащая 6-оксо-6,7,8,9,10,11-гексагидроциклогепта[с]хромен-3-илсульфамат в качестве активного ингредиента и по меньшей мере один фармацевтически приемлемый эксципиент.2. Фармацевтическая композиция по п.1, в которой твердая форма для перорального введения представляет собой желатиновую капсулу.3. Фармацевтическая композиция по п.1, в которой твердая форма представляет собой таблетку.4. Фармацевтическая композиция по п.3, в которой таблетка содержит, в расчете на общую массу композиции, от 1 до 30% активного ингредиента; от 40 до 92% разбавителя; от 0,1 до 20% дезинтегрирующего вещества; от 0,1 до 8% связующего вещества; от 0,1 до 3% способствующего скольжению вещества; и от 0,5 до 3% смазывающего вещества, а также приблизительно 4,8% раствора покрытия в расчете на общую массу покрытой таблетки.5. Фармацевтическая композиция по п.4, в которой разбавитель выбран из следующих эксципиентов: маннит, лактоза или моногидрат лактозы, крахмал, карбонат кальция, микрокристаллическая целлюлоза или мальтодекстрин.6. Фармацевтическая композиция по п.4, в которой дезинтегрирующее вещество выбрано из следующих эксципиентов: крахмал, кроскармеллоза натрия, натрий крахмала гликолят или кросповидон.7. Фармацевтическая композиция по п.4, в которой связующее вещество выбрано из следующих эксципиентов: поливинилпирролидон, сополимеры N-винил-2-пирролидона и винилацетата (или коповидоны), карбоксиметилцеллюлоза, прежелатинизированный крахмал или метилцеллюлоза.8. Фармацевтическая композиция по п.4, в которой смазывающее вещество выбрано из следующих эксципиентов: стеарат магния, стеарилфумарат натрия, стеарат кал�1. A solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta [c] chromen-3-yl sulfamate as an active ingredient and at least one pharmaceutically acceptable excipient. 2. The pharmaceutical composition of claim 1, wherein the solid oral dosage form is a gelatin capsule. The pharmaceutical composition according to claim 1, wherein the solid form is a tablet. The pharmaceutical composition according to claim 3, in which the tablet contains, based on the total weight of the composition, from 1 to 30% of the active ingredient; from 40 to 92% diluent; from 0.1 to 20% of a disintegrant; from 0.1 to 8% binder; from 0.1 to 3% of a glidant; and from 0.5 to 3% of a lubricant, as well as approximately 4.8% of a coating solution, based on the total weight of the coated tablet. The pharmaceutical composition according to claim 4, wherein the diluent is selected from the following excipients: mannitol, lactose or lactose monohydrate, starch, calcium carbonate, microcrystalline cellulose or maltodextrin. The pharmaceutical composition of claim 4, wherein the disintegrant is selected from the following excipients: starch, croscarmellose sodium, sodium starch glycolate, or crospovidone. The pharmaceutical composition according to claim 4, wherein the binder is selected from the following excipients: polyvinylpyrrolidone, copolymers of N-vinyl-2-pyrrolidone and vinyl acetate (or copovidones), carboxymethyl cellulose, pregelatinized starch or methyl cellulose. The pharmaceutical composition according to claim 4, wherein the lubricant is selected from the following excipients: magnesium stearate, sodium stearyl fumarate, calf stearate
Claims (35)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0900656A FR2942226B1 (en) | 2009-02-13 | 2009-02-13 | NEW CRYSTALLINE POLYMORPHATE OF 6-OXO + 6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA ° C! CHROMEN-3-YL SULFAMATE |
FR0900655 | 2009-02-13 | ||
FR0900656 | 2009-02-13 | ||
FR0900655A FR2942225B1 (en) | 2009-02-13 | 2009-02-13 | VARIETY I OF 6-OXO-6,7,8,9,10,11-HEXAHYDROCLYCLOHEPTA5 ° C! CHROMEN-3 YL SULFAMATE OF REDUCED GRANULOMETRY |
PCT/FR2010/000117 WO2010092260A2 (en) | 2009-02-13 | 2010-02-12 | Pharmaceutical compositions of 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2011137516A true RU2011137516A (en) | 2013-03-20 |
Family
ID=42562120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011137516/04A RU2011137516A (en) | 2009-02-13 | 2010-02-12 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOGEPT [c] CHROMEN-3-ILSULFAMATE AND ITS POLYFORM |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2396311A2 (en) |
JP (1) | JP2012517988A (en) |
KR (1) | KR20110115607A (en) |
CN (1) | CN102317276A (en) |
AU (1) | AU2010212753A1 (en) |
BR (1) | BRPI1008422A2 (en) |
CA (1) | CA2751393A1 (en) |
MX (1) | MX2011008239A (en) |
RU (1) | RU2011137516A (en) |
WO (1) | WO2010092260A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018165145A1 (en) * | 2017-03-08 | 2018-09-13 | Ariad Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9603325D0 (en) * | 1996-02-16 | 1996-04-17 | Imperial College | A compound |
US6921776B1 (en) * | 1996-02-16 | 2005-07-26 | Sterix Limited | Compound |
CN1309387C (en) * | 2003-04-15 | 2007-04-11 | 南昌弘益科技有限公司 | Cresol powder with dissolution increased and its preparing method-analgesic, antipyretic and anti-inflammatory agent |
GB0408308D0 (en) * | 2004-04-14 | 2004-05-19 | Vectura Ltd | Pharmaceutical compositions |
GB0511190D0 (en) * | 2005-06-01 | 2005-07-06 | Sterix Ltd | Use |
JP2010510988A (en) * | 2006-11-28 | 2010-04-08 | マリナス ファーマシューティカルズ | Nanoparticle formulation, method for producing the same and use thereof |
-
2010
- 2010-02-12 KR KR1020117021103A patent/KR20110115607A/en not_active Application Discontinuation
- 2010-02-12 CA CA2751393A patent/CA2751393A1/en not_active Abandoned
- 2010-02-12 JP JP2011549626A patent/JP2012517988A/en active Pending
- 2010-02-12 EP EP10707096A patent/EP2396311A2/en not_active Withdrawn
- 2010-02-12 WO PCT/FR2010/000117 patent/WO2010092260A2/en active Application Filing
- 2010-02-12 MX MX2011008239A patent/MX2011008239A/en not_active Application Discontinuation
- 2010-02-12 RU RU2011137516/04A patent/RU2011137516A/en not_active Application Discontinuation
- 2010-02-12 BR BRPI1008422A patent/BRPI1008422A2/en not_active IP Right Cessation
- 2010-02-12 CN CN2010800077893A patent/CN102317276A/en active Pending
- 2010-02-12 AU AU2010212753A patent/AU2010212753A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2010092260A3 (en) | 2011-02-17 |
WO2010092260A8 (en) | 2011-08-11 |
MX2011008239A (en) | 2011-09-06 |
JP2012517988A (en) | 2012-08-09 |
EP2396311A2 (en) | 2011-12-21 |
KR20110115607A (en) | 2011-10-21 |
WO2010092260A2 (en) | 2010-08-19 |
AU2010212753A1 (en) | 2011-09-01 |
BRPI1008422A2 (en) | 2016-03-01 |
CA2751393A1 (en) | 2010-08-19 |
CN102317276A (en) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2470641C2 (en) | Stable formulations of imanitib | |
EP3606511B1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
EP2468361B1 (en) | Vildagliptin Formulations | |
ZA200703866B (en) | Pharmaceutical formulation containing a release rate controlling compositions | |
JP2015533129A (en) | Solid oral pharmaceutical formulation containing ticagrelor | |
CN108135883B (en) | Pharmaceutical composition containing arylalkylamine compound | |
CA2927720A1 (en) | Composite formulation comprising tadalafil and amlodipine | |
US20160120870A1 (en) | The process for the preparation of a pharmaceutical composition comprising rivaroxaban | |
EP3860606B1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
CA2915432A1 (en) | Disintegrant free composition of cinacalcet | |
WO2006134610A1 (en) | Efavirenz pharmaceutical composition having enhanced dissolution profile | |
WO2011080706A1 (en) | Enhanced solubility of ziprasidone | |
CA3085455C (en) | A solid oral dosage form comprising linagliptin | |
RU2463039C2 (en) | Escitalopram and hard pharmacetical composition containing it | |
RU2011137516A (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOGEPT [c] CHROMEN-3-ILSULFAMATE AND ITS POLYFORM | |
JP2023036924A (en) | Pharmaceutical composition containing lenalidomide | |
US20130085145A1 (en) | Imatinib mesilate pharmaceutical tablet | |
WO2019132839A1 (en) | Oral pharmaceutical compositions of dabigatran | |
WO2020055359A2 (en) | Oral dosage form of sorafenib tosylate | |
EP3360542A1 (en) | Tablet forms of vilazodone hydrochloride | |
WO2018033483A1 (en) | Pharmaceutical compositions of a benzothiophene compound | |
WO2017078647A1 (en) | Pharmaceutical compositions of imatinib | |
WO2023128900A1 (en) | Pharmaceutical compositions comprising pimavanserin as active ingredient and relevant excipients | |
NZ764460A (en) | Dosage forms comprising a plasma kallikrein inhibitor | |
JP2020189824A (en) | Tablet containing levetiracetam and manufacturing method of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20141127 |